MIC distribution and inoculum effect of LY333328: A study of vancomycin-susceptible and VanA-type and VanC-type enterococci obtained from intensive care unit patient surveillance cultures

Clinical Microbiology and Infection

Volumn 5, Issue 9, 1999, Pages 554-559

  Cantón, Rafael ^a   Mir, Nuria ^a   Sánchez, Miguel ^b   Baquero, Fernando ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

Inoculum effect; LY333328; Vancomycin resistant enterococci

Indexed keywords

AGAR; AMPICILLIN; GLYCOPEPTIDE; IMIPENEM; ORITAVANCIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; COLONY FORMING UNIT; CONTROLLED STUDY; DILUTION; ENTEROCOCCUS; INTENSIVE CARE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

EID: 0032837452     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1469-0691.1999.tb00434.x     Document Type: Article

References (28)

1. Tailor SA, Bailey EM, Rybak MJ. Enterococcus, an emerging pathogen. Ann Pharmacother 1993; 27: 1231-42.
2. McDonald L, Jarvis WR. The global impact of vancomycin-resistant enterococci. Curr Opin Infect Dis 1997; 10; 304-9.
3. Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clin Infect Dis 1997; 24: 545-6.
4. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance, recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR 1995; 44: 1-13.
5. Landman D, Quale JM. Management due to resistant enterococci: a review of therapeutic options. J Antimicrob Chemother 1997; 40: 161-70.
6. Chadwick PR, Oppenheim BA. Controlling glycopeptide-resistant enterococci. Clin Microbiol Infect 1996; 3: 7-11.
7. Fraise AP, Andrews J, Wise R. Activity of a new glycopeptide antibiotic (LY333328) against enterococci and other resistant Gram-positive organisms. J Antimicrob Chemother 1997; 40: 423-5.
8. Marriott MS. LY333328, a new glycopeptide active against vancomycin-resistant enterococci. Exp Opin Invest Drugs 1995; 4: 1017-19.
9. Nicas TI, Mullen D, Flokowitsch JH, et al. Semisynthetic glycopeptide antibiotics derived from LY264826 active against vancomycin-resistant enterococci. Antimicrob Agents Chemother 1996; 40: 2194-9.
10. Schwalbe RS, McIntosh AC, Qaiyumi S, et al. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci. Antimicrob Agents Chemother 1996; 40: 2416-19.
11. Biavasco F, Vignaroli C, Lupidi R, Manso E, Facinelli B, Varaldo PE. In vitro antibacterial activity of LY333328, a new semisynthetic glycopeptide. Antimicrob Agents Chemother 1997; 41: 2165-72.
12. Facklam R, Collins MD. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 1989; 27: 731-4.
13. de Lencastre H, Severina EP, Roberts RB, Kreiswirth BN, Tomasz A. Testing the efficacy of a molecular surveillance network: methicillin-resistant genotypes in six hospitals in the metropolitan New York City Area. The BARG initiative pilot study group. Bacterial antibiotic resistance group. Microb Drug Resist 1996; 2: 343-51.
14. National Committee for Clinical Laboratory Standards Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically. 4th edn. Publication M7-A4. Wayne, Pa: NCCLS 1997.
15. Woodford N, Morrison D, Johnson AP, Briat V, George RC, Cookson B. Application of DNA probes for rRNA and vanA genes to investigation of a nosocomial cluster of vancomycin-resistant enterococci. J Clin Microbiol 1993; 31: 653-8.
16. Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC. Characterization of glycopeptide-resistant enterococci from US hospital. Antimicrob Agents Chemother 1993; 37: 2311-17.
17. Miele A, Bandera M, Goldstein BP. Use of primers selective for vancomycin resistance genes to determine van genotype in enterococci and to study gene organization in VanA isolates. Antimicrob Agents Chemother 1995; 39: 1772-8.
18. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol 1995; 33: 24-7.
19. Felmingham D, Brown D, Courvalin P, members of the European Workshop on Glycopeptide Resistance. European Glycopeptide susceptibility survey: quality assessment using five reference strains [abstract E34]. In: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1995: 91.
20. Boisivon A, Thibault M, Leclerq R, the Collége de Bactériologie-Virologie-Hygiène des Hôspitaux Généraux Français. Colonization by vancomycin-resistant enterococci of the intestinal tract of patients in intensive care units from French general hospitals. Clin Microbiol Infect 1997; 3: 175-9.
21. Morris, JC Jr., Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin, establishment of endemicity in a university medical center. Ann Intern Med 1995; 123: 250-9.
22. Sahm DF, Free L, Smith C, Eveland M, Mundy LA. Rapid characterization schemes for surveillance isolates of vancomycin-resistant enterococci. J Clin Microbiol 1997; 35: 2026-30.
23. Ayats, J, Ardanuy C, Pérez P, Pujol M, Martín R, Liñares J. Colonización rectal por E. faecalis y E. faecium resistentes a vancomicina (ERV) en pacientes ingresados en UCI [abstract No. 30]. In: Program and abstracts of VII Reunión Nacional de las Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica. Palma de Mallorca: SEIMC 1997: 110.
24. Edmond MB, Ober JF, Weimbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995; 20: 1126-33.
25. Allen NE, Hobbs JN, Nicas TI. Inhibition of peptidoglycan biosynthesis in vancomycin-susceptible and -resistant bacteria by a semisynthetic glycopeptide antibiotic. Antimicrob Agents Chemother 1996; 40: 2356-62.
26. Jones RN, Barret MS, Erwin ME. In vitro activity and spectrum of LY333328, a novel glycopeptide derivative. Antimicrob Agents Chemother 1997; 41: 488-93.
27. Brown DFJ, Courvalin P, the European Glycopeptide Resistance Group. European glycopeptide susceptibility survey: susceptibility of Enterococcus spp. to teicoplanin and vancomycin [abstract E26]. In: Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology, 1996: 85.
28. Mercier RC, Houlihan HH, Rybak MJ. Pharmacodynamic evaluation of a new glycopeptide, LY333328, and in vitro activity against Staphylococcus aureus and Enterococcus faecium. Antimicrob Agents Chemother 1997; 41: 1307-12.